1st Quarter - Report
TIBER CREEK GROUP for ALNYLAM PHARMACEUTICALS, INC.
Firm
Income
$60,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to home infusion under Medicare FFS; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| BRYANT HALL | — |
| JONATHON JONES | — |
| COREY MALMGREN | — |
| TIMOTHY ROBINSON | — |
| JOHN KIRKLAND TWOMEY | — |
| DANIEL HOWARD ZAWITOSKI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.